Literature DB >> 15497159

Posttransplant survival in pediatric fulminant hepatic failure: the SPLIT experience.

Prabhakar Baliga1, Sergio Alvarez, Anne Lindblad, Lan Zeng.   

Abstract

Pediatric patients with fulminant hepatic failure (FHF) tend to be the sickest and have the most urgent need for a liver transplant. The purpose of this analysis was to identify factors associated with posttransplant survival in this subset of patients. Data on all FHF patients registered in the Studies of Pediatric Liver Transplantation (SPLIT) registry from 1995 to 2002 were analyzed. Demographics such as age, gender, race, weight, and etiology of liver disease were recorded. Pretransplant degree of encephalopathy; intubation; dialysis; laboratory parameters such as serum bilirubin and international normalized ratio of coagulopathy (INR); and type of graft: cadaveric whole, cadaveric technical variant, or living donor were analyzed to determine effects on patient survival. Overall, FHF accounted for 12.9% (141 / 1,092) of primary transplants performed between 1995 and 2002. The etiology of liver disease was unknown in the vast majority of children (126 / 141; 89.4%). Mortality while on the waiting list for FHF children is significantly higher than for children with other liver disease (P < .0001). Six-month survival posttransplant for patients with FHF (74.5%) is significantly lower (P < .0001) than those with chronic liver disease (88.9%). A multivariate model demonstrates that the highest risk group includes those children with grade 4 encephalopathy (P < .0001), infants less than 1 year of age (P = .018), and children requiring dialysis prior to transplantation (P = .002). Pretransplant bilirubin and INR were not significant predictors of posttransplant survival after controlling for the other significant factors. Living donor and split / reduced grafts did not have a significantly increased risk of posttransplant death compared to whole grafts. In conclusion, despite advances in the surgical techniques and changes in organ allocation, pediatric patients with FHF continue to have a high pretransplant mortality and less successful posttransplant survival compared to children with chronic liver disease.

Entities:  

Mesh:

Year:  2004        PMID: 15497159     DOI: 10.1002/lt.20252

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  21 in total

1.  Predictors of survival following liver transplantation in infants: a single-center analysis of more than 200 cases.

Authors:  Robert S Venick; Douglas G Farmer; Sue V McDiarmid; John P Duffy; Sherilyn A Gordon; Hasan Yersiz; Johnny C Hong; Jorge H Vargas; Marvin E Ament; Ronald W Busuttil
Journal:  Transplantation       Date:  2010-03-15       Impact factor: 4.939

Review 2.  Coagulopathy and transfusion therapy in pediatric liver transplantation.

Authors:  Mirco Nacoti; Davide Corbella; Francesco Fazzi; Francesca Rapido; Ezio Bonanomi
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

3.  Molecular Absorbent Recirculating System therapy (MARS®) in pediatric acute liver failure: a single center experience.

Authors:  Pierre Bourgoin; Aicha Merouani; Véronique Phan; Catherine Litalien; Michel Lallier; Fernando Alvarez; Philippe Jouvet
Journal:  Pediatr Nephrol       Date:  2013-12-06       Impact factor: 3.714

4.  IL-10 distinguishes a unique population of activated, effector-like CD8+ T cells in murine acute liver inflammation.

Authors:  Julia E Rood; Scott W Canna; Lehn K Weaver; John W Tobias; Edward M Behrens
Journal:  J Leukoc Biol       Date:  2016-12-29       Impact factor: 4.962

5.  Pediatric liver transplantation for acute liver failure at a single center: a 10-yr experience.

Authors:  Thomas G Heffron; Todd Pillen; Gregory Smallwood; John Rodriguez; Sundari Sekar; Stuart Henry; Miriam Vos; Katherine Casper; Nitika Arora Gupta; Carlos G Fasola; Rene Romero
Journal:  Pediatr Transplant       Date:  2009-06-09

6.  Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial.

Authors:  Robert H Squires; Anil Dhawan; Estella Alonso; Michael R Narkewicz; Benjamin L Shneider; Norberto Rodriguez-Baez; Dominic Dell Olio; Saul Karpen; John Bucuvalas; Steven Lobritto; Elizabeth Rand; Philip Rosenthal; Simon Horslen; Vicky Ng; Girish Subbarao; Nanda Kerkar; David Rudnick; M James Lopez; Kathleen Schwarz; Rene Romero; Scott Elisofon; Edward Doo; Patricia R Robuck; Sharon Lawlor; Steven H Belle
Journal:  Hepatology       Date:  2013-02-04       Impact factor: 17.425

Review 7.  Pediatric liver transplantation.

Authors:  Marco Spada; Silvia Riva; Giuseppe Maggiore; Davide Cintorino; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

8.  Pediatric acute liver failure: variations in referral timing are associated with disease subtypes.

Authors:  Ekkehard Sturm; Willem S Lexmond; Henkjan J Verkade
Journal:  Eur J Pediatr       Date:  2014-07-09       Impact factor: 3.183

9.  Acute liver failure: Summary of a workshop.

Authors:  William M Lee; Robert H Squires; Scott L Nyberg; Edward Doo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  Determinants of length of stay after pediatric liver transplantation.

Authors:  Karina Covarrubias; Xun Luo; Allan Massie; Kathleen B Schwarz; Jacqueline Garonzik-Wang; Dorry L Segev; Douglas B Mogul
Journal:  Pediatr Transplant       Date:  2020-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.